



SideROS Announces 500k€ Seed Funding to Tackle Relapse & Metastasis in Cancer

Paris, April. 23, 2020 -- SideROS, a French biotechnology company at preclinical stage, founded in January 2019, based on the research from Dr Raphaël Rodriguez, a world-renowned scientist devoted to understanding the biology of persister cancer cells and the underlying role of iron homeostasis, designed a drug to eradicate these cells, announces that it has closed a 500k€ seed round with participation from Business Angels with international expertise in pharmaceutical industry. This funding will be completed by a 170 k€ grant from Bpifrance as SideROS is a 2019 iLAB laureate.

"With the support of our past and new investors, we will accelerate the preclinical development of our drug candidate ironomycin and continue to work on cancer stem cell biology" said Raphaël Rodriguez, co-Founder of SideROS.

With this funding, SideROS will mainly address two major development steps:

- Pharmaceutical development: select the subcontractor in charge of the manufacturing of our active pharmaceutical ingredient (API) candidate (ironomycin) and manufacture a first scaled-up batch in industrial environment in order to ensure the further manufacturing of a GMP API batch.
- Nonclinical development: conduct DMPK studies based on a solid evaluation plan to gather solid results by Q4 2020, in parallel to pharmacology studies in various indications and animal models to consolidate our clinical development plan.

"This investment from qualified Business Angels in pharmaceutical industry allows us to run strategic development steps, such as scaling-up of our manufacturing process and DMPK characterization correlated to proof of concept in animals, to move forward to the design of our first clinical trial", said Lucie Mondoulet, CEO at SideROS.

Nathalie Donne, co-founder & partner at Shape N Link Consulting is very proud to have supported SideROS first funding to raise a seed amount allowing the company to accelerate their development of a first drug candidate aiming to tackle a major burden.

About SideROS

SideROS bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells, refractory to conventional treatments and associated to metastasis and relapse. The role of iron is ubiquitous in cancer, suggesting that our small molecules can target various types of cancer. SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking effective treatments. SideROS has received Deeptech label from Bpifrance in 2019. (www.sideros.bio; <https://www.linkedin.com/company/sideros-bio>)

Lucie Mondoulet
CEO
+33 (0)6 62 59 04 17
Lucie.mondoulet@sideros.bio

Nathalie Donne
Business Advisor
+33 (0)6 67 67 44 97
Nathalie.donne@shapenlink.com

bpifrance
SERVIR L'AVENIR

La FRENCH
 TECH

i-Lab

RISE
CNRS
INNOVATION

 hello
tomorrow

 **Biofit** FOSTERING
INNOVATION
& TRANSFER

 **iPEPS**
INCUBATEUR
by ICM

ME
di
CEN
PARIS
REGION

france
biotech
biotech | medtech | e-santé | IA
LES ENTREPRENEURS DE LA HEALTHTECH